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Activated NF-jB in Bone Marrow Mesenchymal Stem Cells
from Systemic Lupus Erythematosus Patients
Inhibits Osteogenic Differentiation Through
Downregulating Smad Signaling
Yu Tang,1 Hao Xie,2 Jinyun Chen,1 Linyu Geng,1 Haifeng Chen,1 Xia Li,1 Yayi Hou,2 Liwei Lu,3
Songtao Shi,4 Xiaofeng Zeng,5 and Lingyun Sun1
Osteoporosis in patients with systemic lupus erythematosus (SLE) is thought to be the result of accelerated
osteoclastogenesis induced by pro-inflammatory cytokines such as tumor necrosis factor (TNF). However, the
molecular mechanisms involved in the osteoblastogenesis in SLE patients are not fully understood. We investi-
gated the bone morphogenetic protein-2 (BMP-2)-induced osteoblastic capacity of bone marrow-derived mesen-
chymal stem cells (BMMSCs) from SLE patients and the TNF signaling system in determining BMP-2-induced
regulatory pathways. It showed that the capacity of osteogenic differentiation of BMMSCs from SLE patients was
reduced compared with that from healthy controls. The nuclear factor kB (NF-kB) signaling was activated while
the BMP/Smad pathway was repressed in BMMSCs from SLE patients. TNF activated NF-kB pathway and
inhibited the phosphorylation of Smad 1/5/8 and BMP-2-induced osteoblastic differentiation in BMMSCs from
normal controls, while addition of pyrollidine dithiocarbamate (PDTC), an NF-kB inhibitor, to SLE-BMMSCs could
partially reverse these effects. Thus, our findings have shown that the activated NF-kB pathway in SLE-BMMSCs
inhibits the BMP-2-induced osteoblastic differentiation through BMP/Smad signaling pathway, suggesting that
the impaired osteoblastic differentiation may participate in the pathology of osteoporosis in SLE patients.
Introduction
Systemic lupus erythematosus (SLE) is a chronic, mul-tisystemic autoimmune disease that involves multiple or-
gans including renal, cardiovascular, neural, musculoskeletal,
and cutaneous systems. Osteoporosis (OP), a metabolic bone
disease characterized by decreased bone mineralization, in-
creased bone fragility, and increased risk of fracture, has been
found to be prevalent in patients with SLE. Cross-sectional
studies have shown an increased prevalence of OP in SLE
patients, which is estimated to be between 4% and 22% [1–3].
The mechanisms of OP in SLE patients remain incom-
pletely understood and may include the inflammatory dis-
ease itself, disease-related comorbidity, and the treatment of
the disease including the corticosteroids (CS). Although ex-
posure to CS is generally considered to be a major factor
contributing to the development of OP, the systemic in-
flammation itself is recognized to be the most important risk
factor of OP in SLE patients. Tumor necrosis factor (TNF) is
one of the most potent pro-inflammatory cytokines and is
known to be a catabolic factor in the inflammatory reaction
of diseases such as rheumatoid arthritis (RA) [4]. SLE pa-
tients are reported to have increased TNF in its serum [5,6].
TNF induces osteoclastogenesis either by promoting the
proliferation of osteoclast precursor cells or by causing the
activation of the differentiated osteoclast through RANK/
RANKL signaling pathway [7–9]. TNF stimulates osteoclasts
to express RANK to interact with its ligand RANKL to ac-
celerate the activity of osteoclasts.
Indeed, in physiologic remodeling, activation of bone re-
sorption requires contact between cells of the osteoblast and
osteoclast lineages. Osteoblasts play an essential role in the
pathogenesis of OP. Osteoblasts produce RANKL, which
activates the differentiation of osteoclasts and maintains their
bone resorptive function. Osteoblasts also produce and
secrete osteoprotegerin, a decoy receptor that can block
RANKL/RANK interactions [10,11]. Since bone mass loss in
SLE is believed to be associated with TNF system, it has also
been hypothesized that TNF directly controls osteoblast
survival and/or its function [12]. However, the role of TNF
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signaling in modulating osteoblast’s function and differen-
tiation remains controversial. Some groups reported that
treatment of human mesenchymal stem cells (MSCs) with
TNF during differentiation resulted in enhanced expression
of osteogenic markers [13,14]. On the contrary, other studies
have demonstrated that TNF blocked osteoblast differentia-
tion in multiple model systems such as fetal calvaria, bone
marrow (BM) stromal cells, and MC3T3-E1 cells [15–17].
Moreover, both spontaneous and bone morphogenetic pro-
tein (BMP)-induced osteoblast differentiation could be in-
hibited by TNF in vitro [18,19].
Osteoblasts are derived from MSCs, which can differen-
tiate into osteoblasts both in vitro and in vivo [20,21]. We
have previously reported that bone marrow-derived mes-
enchymal stem cells (BMMSCs) from SLE patients showed
significantly decreased bone-forming capacity and impaired
reconstruction of BM osteoblastic niche in vivo [22]; how-
ever, the cellular mechanism underlying this deficiency has
not yet been elucidated.
BMPs, members of the transforming growth factor (TGF)-b
superfamily, have been shown to play critical roles in gov-
erning various aspects of embryological development, in-
cluding brain, heart, kidney, and eye [23]. BMPs are also
known to promote the differentiation of MSCs into chon-
drocytes and osteoblasts and the differentiation of osteopro-
genitor cells into osteoblasts through the Smad signaling
transduction pathway via 2 transmembrane serine-threonine
kinase receptors, BMP receptor (BMPR) type I and BMPR type
II [24]. The activated receptor kinases, in turn, phosphory-
late the transcription factors Smad 1, 5, and 8. The phos-
phorylated Smads then form a heterodimeric complex with
Smad 4 in the nucleus and activate the expression of target
genes. In this study, we investigated the nuclear factor kB
(NF-kB) and BMP/Smad signaling pathways in the
BMMSCs from SLE patients. We demonstrated the role of
TNF activated NF-kB pathway in regulating osteoblastic
differentiation and found that the activated NF-kB pathway
of BMMSCs from SLE patients inhibited BMP-2-induced
osteogenic differentiation through downregulating Smad
signaling pathway. Together, our results have uncovered a
novel mechanism that TNF participates in the pathology of
OP in SLE patients.
Materials and Methods
Patients and controls
BM cells for cDNA microarray were obtained from 4 pa-
tients with SLE, according to the American College of Rheu-
matology [25], (Supplementary Table S1; Supplementary
Data are available online at www.liebertpub.com/scd). All
the patients were female with the mean age of 37– 11 years
(range 20–44). The normal controls were 1 male and 3 fe-
males, with the mean age of 39– 7 years (range 29–45). MSCs
from 10 SLE patients (mean 37– 13 years, range 15–57 years)
and 10 age- and sex-matched normal controls were examined
for various osteoblastic markers by quantitative reverse
transcriptase-polymerase chain reaction (qRT-PCR) analysis.
Three to five of these 10 samples mentioned above were used
for western blot analysis. All the SLE patients above had
active disease with a Systemic Lupus Erythematosus Disease
Activity Index (SLEDAI) [26] score of more than 8 at the time
of BM aspiration. Serum from 16 patients (15 females and 1
male, mean age of 33–14 years, range 13–57, SLEDAI: 2–21)
and 15 female normal controls (mean age of 32– 13 years,
range 16–57) were tested for BMP-2 levels (Supplementary
Table S2). All participants gave written consent to the
study, which was approved by the Ethics Committee of the
Affiliated Drum Tower Hospital of Nanjing University Medi-
cal School [27].
Cell culture and flow cytometry
BM samples were taken from the iliac crest of SLE pa-
tients and healthy subjects. The BM mononuclear cells were
plated at 105/mL density in low glucose Dulbecco modified
Eagle medium (L-DMEM; Gibco) supplemented with 10%
heat inactivated fetal bovine serum (Invitrogen) and 1% anti-
biotic-antimycotic and incubated at 37C in a 5% (vol/vol)
humidified CO2 chamber as described previously (27). Mar-
kers CD29, CD44, C105, CD34, CD45, and HLA-DR on the
cells at passage 2 were consequently detected by flow cy-
tometry [27].
Cells at passage 3–5 were plated on a 6-cm dish (2.5 · 104/
mL) and were grown to confluence for 3 days at 37C in 5%
CO2 and then stimulated with osteogenic medium including
10mM b-glycerophosphate (GP; Sigma), 50mg/mL ascorbic
acid (AA; Sigma), and 300 ng/mL BMP-2 (Miltenyi Biotec)
for 2, 14, or 21 days.
RNA extraction and quantitative real-time
RT-PCR analysis
BMMSCs from SLE patients were cultured in a 6-well
plate (2.0 · 105 viable cells), and treated with indicated con-
centrations of TNF (R&D), BMP-2, pyrollidine dithiocarba-
mate (PDTC), or both of them for indicated times; BMMSCs
in the presence or absence of stimulation were placed in
TRIzol (Invitrogen) and total cellular RNA was extracted.
cDNA was synthesized using PrimerScript RT reagent Kit
(TaKaRa). qRT-PCR was performed on an ABI 7500 FAST
real-time PCR detection system (Applied Biosystems) using
SYBR Green detection mix [25]. The following primers were
used in this study: alkaline phosphatase (ALP) Sense 5¢-
GCACCGTCAAGGCTGAG AAC-3¢, Antisense 5¢-TGGTGA
AGACGCCA GTGGA-3¢; Runx2 Sense 5¢, CACTGGCGC
TGCAACAAGA-3¢, Antisense 5¢-CATTCCGGAGCTCAGC
AG AATAA-3¢; osteocalcin (OCN) Sense 5¢-CGGTGCAGA
GT CCAGCAAAG-3¢, Antisense 5¢-TACAGGTAGCGCCTGG
GTCTCT-3¢; COLIA2 Sense 5¢-GAGGGCAACAGC AGGTTCA
CTTA-3¢, Antisense 5¢-TCA GCACCAC CGATGTCCA-3¢; and
(GAPDH) sense: 5¢-TGACTTCAACAGCGACACCCA-3¢, an-
tisense: 5¢-CACCCTGTTG CTGTAG CCAAA-3¢.
The expression of the target genes in SLE samples as
compared with that in controls was examined using 2 -DDCt
method. Briefly, for each sample, a value for the cycle
threshold (Ct) was determined, defined as the mean cycle at
which the fluorescence curve reached an arbitrary threshold.
The DCt for each sample was then calculated according to
the formula Ct target gene -—Ct GAPDH; DDCt values were
then obtained by subtracting the DCt of a reference sample
(average DCt of the control group) from the DCt of the
studied samples. Finally, the levels of expression of the target
genes in the studied samples as compared with the reference
sample were calculated as 2-DDCt.
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cDNA microarray analysis
BMMSCs at passage 3 from 4 patients and 4 normal con-
trols were placed in Trizol (Invitrogen) and processed for
RNA extraction using the RNeasy kit according to the in-
structions of the manufacturer (Qiagen). The universal hu-
man reference RNA samples (Stratagene Corporation) were
used as a common reference in the 2 channel microarrays.
Total RNA was reverse-transcribed, and the cDNA of
BMMSCs from SLE patients and controls were added with
Cy3-dCTP while the cDNA of human reference were added
with Cy5-dCTP in the presence of Klenow enzyme (GE
Healthcare Cat. No. PA 55021/PA 53021) [28].
Microarray analysis was performed in CapitalBio Corp
using 22K Human Genome Array. Labeled samples were
quantitatively adjusted based on the efficiency of Cy-dye
incorporation and mixed into 80mL hybridization solution
[3 · saline sodium citrate (SSC), 0.2% sodium dodecyl sulfate
(SDS), 25% formamide, and 5· Denhart’s]. DNA in hy-
bridization solution was denatured at 95C for 3min prior
loading on a microarray. The array was hybridized at 42C
overnight and washed with 2 consecutive washing solutions
(0.2% SDS, 2 · SSC at 42C for 5min and 0.2% SSC) for 5min
at room temperature. Finally, arrays were scanned with a
confocal LuxScan 10 KA scanner (CapitalBio).
The data of obtained images were extracted with LuxScan
3.0 software (CapitalBio). Genes with the signal intensity
more than 800 (Cy3 or Cy5) were regarded as the expressed
genes. In every 2 channel slides, the intensity ratio of the Cy3
to Cy5 of each spot was calculated after normalization with
LOWESS regression. Statistical data and differential analysis
files were generated by using SAM software 3.0 (Stanford
University). The significantly changed genes were selected
based on P-value < 0.05 and > 2-fold as criteria. All the dif-
ferentially expressed genes were analyzed using a free web-
based Molecular Annotation System 2.0 (MAS 2.0, http://
bioinfo.capitalbio.com/mas).
All data are MIAME compliant and that the raw data have
been deposited in a MIAME compliant database (GEO). The
raw data can be seen at www.ncbi.nlm.nih.gov/geo/query/
acc.cgi acc, =GSE 21649 and the accession number is GSE 21649.
ALP staining
Fourteen days after stimulation, BMMSCs were washed
twice with phosphate-buffered saline, fixed with 0.5mL/well
formalin/methanol/H2O (1:1:1.5) for 15min at room temper-
ature, and washed thrice with distilled water. For staining, 1
FAST5-bromo-4-chloro-3-indolylphosphate/nitro blue tetra-
zolium tablet (Sigma) was dissolved in 10mL of water, and
0.5mL of substrate solution was added to the fixed cultures
for 15min at room temperature. After staining, cultures were
washed thrice with distilled water and air-dried.
Alizarin Red S staining for mineralization
Twenty-one days after stimulation, BMMSCs were wa-
shed twice in phosphate-buffered saline, fixed with 0.5mL/
well formalin/methanol/H2O (1:1:1.5) for 15min at room
temperature, and washed thrice. Saturated Alizarin Red S
solution (pH 4.1) was filtered, and 1.5mL/well was added
and incubated for 5min at room temperature. Cells were
then washed 4–5 times and air-dried.
Western blotting analysis
Cells (2· 105 viable cells) were precultured in 6-well plates
in DMEM containing 10% fetal calf serum for 48 h. After
preculture, the medium was replaced with serum-free fresh
medium, and then indicated concentrations of BMP-2, TNF,
or PDTC were added to the culture medium for different
time intervals. After stimulation, cells were lysed with SDS-
sample buffer containing 20mM Tris-HCl (pH 7.6), 250mM
NaCl, 0.5% NP-40, 3mM ethylenediaminetetraacetic acid,
and 1.5mM ethyleneglycoltetraacetic acid with 10mg/mL
Aprotinin, 10mg/mL leupeptin, 1mM DTT, 1mM para-
nitrophenylphosphate, and 0.1mM Na3VO4 as protease
and phosphatase inhibitor. Cell lysates were separated by
sodium dodecyl sulfate-polyacrylamide gel electrophoresis
(SDS-PAGE) and transferred to a polyvinylidene difluoride
(PVDF) membrane (Millipore). Blots were probed by anti-
phospho-Smad1/5/8 antibodies (Cell Signaling Technology,
Inc.), anti-total-Smad1/5/8 antibodies (Santa Cruz Bio-
technology, Inc.), anti-Sma4 antibodies (Cell Signaling
Technology, Inc.), anti-inhibitor kB (IkB) antibody (Cell Sig-
naling Technology, Inc.), and anti-GAPDH antibody (Milli-
pore) before visualizing with horseradish peroxidase-
conjugated secondary antibodies followed by development
with FluorChem FC2 System (Alpha Innotech Corporation).
Immunoprecipitation analysis
BMMSCs from patients and healthy controls were starved
in serum-free fresh medium for 24 h and stimulated with
BMP-2 for 30min, then lysed with (SDS)-sample buffer, and
diluted to 1mg/mL. Anti-Smad1/5/8 antibodies were added
to 1mL cell lysates at 4C overnight. The immunocomplex
was captured by adding 100mL Protein A Agarose, Fast
Flow, bead slurry (Millipore). After incubation at 4C for 2 h,
the carrier beads were washed 4 times in buffer. The samples
were boiled in Laemmli loading buffer for 10min, applied to
10% SDS-PAGE gels, and electroblotted onto PVDF western
blot membranes (Roche Diagnostics). The Smad4 protein
was identified by western blot analysis.
Enzyme-linked immunosorbent assay analysis
Serum samples from 16 SLE patients and 15 healthy con-
trols were collected, and the concentrations of BMP-2 of each
individual were measured using commercial ELISA kit
(R&D) according to the manufactory introduction.
Statistical analysis
All results are shown as mean – standard error of the mean
of data from at least 3 separate experiments, each performed
with triplicate samples. Differences between groups were
analyzed for statistical significance using analysis of vari-
ance. Differences between 2 independent groups were ana-
lyzed for student’s t-test (SPSS 16.0 software). P values < 0.05
were accepted as statistically significant.
Results
Characterization of osteoblastic differentiation
in BMMSCs from SLE patients
Consistent with our previous findings, BMMSCs from both
SLE patients and normal controls were positive for CD29,
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CD44, and CD105, and negative for CD14, CD34, CD45, and
HLA-DR. There was no significant difference between the
phenotypic features of MSCs from SLE patients and normal
controls [27]. To exclude the effect of senescence on the oste-
ogenic capacity of BMMSCs, we compared the proliferation of
BMMSCs during the culturing of osteogenic medium with
BMP-2 (OMB) (AA, GP, and BMP-2). The growth curves
showed that both the 2 groups rapidly grew from about the
9th day and reached the highest level at the 14th day. Cell
amount decreased after 14 days during the osteogenic me-
dium culture. There was no difference between the cell
numbers of normal controls (n= 3) and SLE patients (n= 3) at
every point (all P> 0.05; Fig. 1A). And then, we evaluated the
osteogenic capacity of BMMSCs from SLE patients induced by
FIG. 1. Characterization of osteoblastic differentiation in BMMSCs from SLE patients. (A) The growth curves of BMMSCs during
osteogenic differentiation from SLE patients and normal controls. Two groups of cells were cultured in the osteogenic medium with
BMP-2 (OMB) for0*18days. (B)StimulationwithdifferentdosesofBMP-2ontheBMMSCs.Cellswerestarvedfor24h,andstimulated
for 30min with different concentrations of BMP-2. The phosphorylated Smad1/5/8 was detected by western blotting analysis. (C)
Alkalinephosphatase (ALP) stainingof cells for 14days andAlizarinRedS staining for 21days after treatmentwithOMB. *P<0.05 and
**P<0.01versus control groups.ALP-positive cells are stainedas blue, andmineralization is visible as red spotson thephotos shown. (D)
qRT-PCRanalysis of osteoblasticmarkers after osteogenic stimuluswithBMP-2 for 2days. The relativemRNAlevelswere analyzedby
comparing with normal groups. (E) qRT-PCR analysis of ALP activity on day 14. **P<0.01 versus indicated groups. (F) The area of
mineralized nodules of BMMSCs from SLE patients and healthy controls. **P<0.01 versus normal control groups (n=3). Nor, normal
controls; SLE, systemic lupus erythematosus, BMMSCS, bonemarrow-derivedmesenchymal stem cells; BMP-2, bonemorphogenetic
protein-2; qRT-PCR, quantitative reverse transcriptase-polymerase chain reaction.
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OMB. As BMP-2 activates Smad signaling pathway via the
phosphorylation of Smad1/5/8, we firstly treated BMMSCs
with different concentrations of BMP-2 to find that BMP-2
induced the pSmad1/5/8 in a dose-dependent manner, so we
selected 100ng/mL BMP-2 in the following experiments (Fig.
1B). Before stimulation, BMMSCs from both SLE and control
subjects showed a low expression of ALP, Runx2, OCN, and
collagen II A2 (CoIIA2) at the transcriptional level. In response
to OMB treatment for 2 days, BMMSCs from both groups
showed a significant increase in mRNA levels of ALP, CoIIA2,
Runx2, and OCN. Of note, BMMSCs from SLE patients
showed lower expression of ALP, CoIIA, and Runx2 post-
stimulation as compared with that from the normal controls,
while no statistical difference could be found in OCN mRNA
level between these 2 groups (Fig. 1C). In addition, after a
longer exposure to osteogenic stimulus, the ALP activity and
the area of the mineralized nodules were lower in SLE-
BMMSCs as detected by ALP and Alizarin Red S staining on
day 14 and 21, respectively (Fig. 1D). These results suggested
BMMSCs from SLE patients display impaired capacity of os-
teoblastic differentiation.
Repressed BMP/Smad and activated NF-jB
signaling pathways in BMMSCs from SLE patients
As many signaling pathways like Wnt, Notch, fibroblast
growth factors, and BMP/Smad pathways [29–32] are in-
volved in the osteoblastic differentiation of MSCs, we com-
pared the gene expression profiles of BMMSCs between SLE
patients and normal controls, and found that all the differ-
entially expressed genes in BMP/TGF-b signaling pathway
except for BMP5 were downregulated in the patients’ cells
(Fig. 2A). Western blot analysis revealed that the Smad1/5/8
phosphorylation was higher in normal BMMSCs 30min after
BMP-2 stimulation (Fig. 2B). Moreover, the complex of
Smad1/5/8 and Smad4, which was translocated into nucleus
for the initiation of the mRNA transcription of target genes
such as Runx2, was also reduced in SLE-BMMSCs compared
with normal BMMSCs by immunoprecipitation analysis (Fig.
2C). These results revealed a suppressed BMP/Smad sig-
naling pathway in SLE-BMMSCs. It was previously reported
that TNF could inhibit bone formation and osteoblastic dif-
ferentiation induced by BMPs [15,16] through NF-kB sig-
naling pathway [33], besides, higher level of TNF was found
in the serum of SLE patients compared with normal controls
[5,6]. We next examined the state of NF-kB signaling path-
way in BMMSCs from SLE patients, and found that the
phosphorylated inhibitor kB kinase b (IKKb) was higher. As
the target of the IKK complex, the IkB was phosphorylated
and subsequently degraded and decreased. We further
found that the level of IkB was decreased in SLE-BMMSCs
(Fig. 2D), which suggested an activated status of the NF-kB
pathway in the patients’ cells.
Activation of NF-jB inhibited BMP-2-induced
expression of osteogenic markers in BMMSCs
from normal controls
Next, we investigated the effect of TNF on the phos-
phorylation of Smad1/5/8 through NF-kB signaling path-
way in BMMSCs from normal controls. Following 2-h
pretreatment with TNF, BMMSCs were stimulated with
BMP-2 for 30min. As shown in Fig. 3A, TNF inhibited the
phosphorylation of Smad1/5/8 induced by BMP-2 in a dose-
dependent manner. TNF (20 ng/mL) alone effectively acti-
vated the NF-kB pathway as detected by the decreased IkB,
but it had no effect on the activation of Smad1/5/8; never-
theless it could inhibit the Smad1/5/8 phosphorylation in-
duced by BMP-2 (Fig. 3B). To further observe whether TNF
inhibited the Smad1/5/8 phosphorylation through NF-kB
pathway, PDTC, an NF-kB inhibitor was added to the BMP-
2-TNF system. As shown in Fig. 3C, PDTC, at the concen-
tration of 50 and 100 nM, reversed the inactivation of
Smad1/5/8 caused by TNF. These data collectively indicate
that the activation of NF-kB inhibits the BMP/Smad signal-
ing pathway.
For further investigation of the mechanism by which NF-
kB affects the BMP-induced osteblastic differentiation, we
examined the mRNA levels of ALP and Runx2 and the ex-
tracellular mineralization in normal BMMSCs treated with
BMP-2 and/or TNF. Consistent with the western blot results,
TNF inhibited ALP activity and Runx2 mRNA expression
induced by BMP-2 for 48 h (Fig. 3D). Moreover, TNF in-
hibited BMP-2 induced extracellular mineralization on day
21 (Fig. 3E).
PDTC restored BMP-2-induced osteoblastic
differentiation of BMMSCs from SLE patients
Next, we investigated whether inhibiting the activation of
NF-kB could restore the osteoblastic differentiation of
BMMSCs in SLE patients. Although PDTC alone had no ef-
fect on the phosphorylation of Smad1/5/8, it increased the
phosphorylation of Smad1/5/8 induced by BMP-2 in the
absence of exogenous TNF (Fig. 4A). Similarly, PDTC en-
hanced the levels of Runx2 and ALP mRNA treated with
BMP-2 for 48 h (Fig. 4B). After exposure to osteogenic stim-
ulus for 21 days, PDTC increased the mineralization of
BMMSCs from SLE patients, although it did not restore it to
the level of normal cells (Fig. 4D).
The circulating levels of BMP-2 in patients with SLE
BMP-2 is secreted by osteoblasts to bone matrix and also is
one of the markers of osteoblastogenesis bone formation.
Although we hardly detected BMP-2 in the BM of SLE pa-
tients, the level of BMP-2 in the serum of the patients (n= 16)
was lower than normal controls (n = 15), suggesting a de-
creased osteoblastogenesis in SLE patients (Fig. 5).
Discussion
BMMSCs from SLE patients demonstrated early signs of
senescence [34,35]. SLE-BMMSCs were also observed to
grow slower than the normal controls in ordinary cultural
medium [27,34]. However, in this study, we did not find the
difference in the proliferation rates between the 2 groups in
the OMB. Different from the ordinary cultural medium, the
numbers of the BMMSCs in OMB decreased after about 14
days, suggesting an enhanced trend to differentiation. The
growth curve excluded the effect of senescence on the oste-
oblastic differentiation.
Both patients and normal BMMSCs cultured in ordinary
medium showed extremely low levels of all the osteogenic
markers, confirming that BMMSCs, even for a long period of
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FIG. 2. Repressed BMP/Smad
and activated NF-kB signaling
pathways in BMMSCs from SLE
patients. (A) Clustering analysis of
genes in BMP/TGF-b signaling
pathway in BMMSCs from SLE
patients and healthy controls. (B)
Western blotting analysis of phos-
phorylated Smad1/5/8 of BMMSCs
from SLE patients and healthy
controls. Cells were starved (the left)
and incubated with BMP-2 (100 ng/
mL) for 30min (the right). (C) Im-
munoprecipitation (IP) analysis of
BMMSCs from SLE patients and
healthy controls. (D) Western blot-
ting analysis of P IKKb, t IKKb, and
IkB in BMMSCs from SLE patients
and healthy controls. (E–H) Quan-
tity analysis of western blotting
analysis. *P < 0.05 and **P < 0.01
versus normal control groups. Nor,
normal controls, SLE, systemic lu-
pus erythematosus, Nor +BMP-2,
normal BMMSCs stimulated with
BMP-2; SLE+BMP-2, SLE-BMMSCs
stimulated with BMP-2; TGF-b,
transforming growth factor-b; NF-
kB, nuclear factor kB; IkB, inhibitor
kB; IKKb, inhibitor kB kinase b.
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FIG. 3. Effect of activating NF-kB signaling pathway on BMP-2-induced osteogenic markers in normal BMMSCs. (A) Effect
of different concentrations of TNF on the Smad1/5/8 phosphorylation in BMMSCs revealed by western blotting analysis.
BMMSCs were starved for 24 h and subsequently stimulated with TNF for 2 h and BMP-2 for 30min. (B) Effect of TNF
(20 ng/mL) on the levels of IkB and phosphorylation of Smad1/5/8 induced by BMP-2. (C) Effect of PDTC on the Smad1/5/
8 phosphorylation in the presence of BMP-2 (100 ng/mL) and TNF (20 ng/mL). Starved cells were treated with TNF and
PDTC for 2 h, followed by BMP-2 for 30min. (D) qRT-PCR analysis of ALP and Runx2 mRNA levels. Cells were treated with
TNF or BMP-2 for 48 h. *P < 0.05 and **P < 0.01 versus controls or between the indicated groups (n = 4). (E) Alizarin Red S
staining of cells cultured in the OMB for 21 days in the presence or absence of TNF. (F) The quantity analysis of mineralized
nodules of normal BMMSCs in the OMB for 21 days in the presence or absence of TNF. *P < 0.05 versus normal control groups
(n = 3). TNF, tumor necrosis factor; PDTC, pyrollidine dithiocarbamate.
FIG. 4. Effect of PDTC on BMP-2 induced osteogenic differentiation in SLE-BMMSCs. (A) Western blotting analysis of
phosphorylated Smad1/5/8 stimulated with PDTC (100 nM) and/or BMP-2 (100 ng/mL). Cells were starved for 24 h and
treated with PDTC for 2 h, followed by BMP-2 for 30min. (B) qRT-PCR analysis of ALP and Runx2 mRNA levels. Cells were
treated with PDTC and/or BMP-2 for 48 h. *P< 0.05 and **P < 0.01 versus controls or between the indicated groups (n= 3). (C)
Alizarin Red S staining of SLE-BMMSCs cultured in the OMB for 21 days in the presence or absence of PDTC. (D) Quantity
analysis of mineralization area. *P < 0.05 and **P < 0.01 versus normals or between the indicated groups (n= 3). Nor, normal
controls; SLE, systemic lupus erythematosus.
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time in culture, cannot differentiate into osteoblasts without
osteogenic stimulation [36]. After stimulating with BMP-2 for
2 days, the mRNA levels of ALP, ColIIA2, OCN, and Runx2 in
BMMSCs were increased. Besides, the mRNA levels of
aforementioned genes in BMMSCs from SLE patients were
lower than that from normal controls except for OCN. The
ALP activity (at day 14) and the mineralized level (at day 21)
were also lower in SLE patients compared with normal
subjects. All the results mentioned above indicated there was
a defective capacity of SLE-BMMSCs to differentiate into
osteoblasts. OCN, one of the later markers of osteoblast dif-
ferentiation compared with ALP and Runx2, was reported to
be induced at the third day on MC3T3 cells [37] or at the
sixth day on RD-C6 cells [38] induced by BMP-2. Therefore,
the difference in OCN expression between BMMSCs from
SLE patients and normal controls may not be detected at day
2 of culture.
Our results differ from findings by Nie et al., which sug-
gested a similar ability of MSCs differentiating into osteo-
blasts between SLE patients and healthy subjects [34]. The
underlying reasons responsible for this discrepancy remains
unclear, but several possibilities might exist: since MSCs in
vitro have been recognized to represent heterogeneous
group of progenitors with different self-renewal properties
[39], MSCs of different passages may have distinct capacity
of differentiation [40]; moreover [41], the osteoblastic differ-
entiation may change with the alternations of cytokines in
the osteoblastic medium [42]; some medications, such as
glucocorticoid (GC) [43,44], methotrexate, and warfarin may
affect the osteoblastic capacity of MSCs [45]; at last, in the
study of Nie et al. [34] the quantitative analysis of Alizarin
Red S staining had not been measured.
In this study, cDNA microarray analysis revealed 19 dif-
ferentially expressed genes in BMP/TGF-b signaling path-
way. Among them, 18 genes were downregulated, including
Smad1, Smad5, BMPRIA, and Id1 (inhibitor of differentiation
or inhibitor of DNA binding-1). Moreover, the lower level of
Smad1/5/8 phosphorylation and the decreased complex of
Smad1/5/8 with Smad4 confirmed the decreased BMP/
smad signaling pathway in SLE-BMMSCs.
Several possible mechanisms may be responsible for the
reduction of Smad1/5/8 phosphorylation: First, the inactive
status of BMPR (BMPR I and BMPR II) because of the weak
stimulation of BMPs in BM or the intrinsic defect of the re-
ceptors; second, the regulation of cytokines or growth factors
that directly inhibits the Smad1/5/8 phosphorylation. We
found in this study that the protein level of BMPR-IA did not
change as analyzed by western blot (Supplementary Fig. S1),
although we found the level of BMP-2 in the serum of SLE
patients was lower than normal controls. It has been shown
that many BMPs, including BMP2, BMP6, BMP7, and BMP9
may induce osteoblast lineage-specific differentiation of
MSCs [46–48], and the total amount of BMP activity is more
important than the activity of a specific BMP [49]; moreover,
other BMPs may be able to compensate for the loss of one
BMP [50]. Therefore, with the normal BMPR-IA, the total
amount of BMPs in SLE-BMMSCs might remain unchanged.
Thus, our data suggest that the change in BMP/Smad sig-
naling pathway likely results from the function of other cy-
tokines or growth factors in the BM.
TNF is a potent inflammatory cytokine that contributes to
local and systemic bone loss in inflammatory bone diseases
such as RA, periodontitis, and multiple myeloma, and in
estrogen deficiency [51–54]. It is now well known that TNF
can induce osteoclastogenesis both in vivo and in vitro.
However, the effect of TNF on the differentiation or matu-
ration of osteoblast and their mechanisms remain unre-
solved: TNF may enhance the osteoblastic differentiation
through NF-kB pathway [13,14], or it activates SAPK/JNK,
ERK1/2, and Ras/Rho-MAPK signaling pathway to inhibit
the spontaneous or BMP-2nduced osteoblastic differentiation
[18,19]. We found here that TNF inhibited BMP-2-induced
osteoblastic differentiation of BMMSCs from normal con-
trols. We further found that TNF inhibited the osteoblastic
differentiation of BMMSCs by inactivating Smad1/5/8, and
NF-kB inhibition restored the activation of Smad1/5/8.
These data collectively indicate that the inhibitory effect of
TNF is attributed to, at least in great part, the activation of
NF-kB.
In the current study, we found that the NF-kB activity was
increased while the BMP signaling induced by BMP-2 was
inactive in BMMSCs from SLE patients. Importantly, NF-kB
inhibitor, PDTC, restored the activation of BMP signaling
and subsequent ostoblastic markers and mineralization of
BMMSCs from SLE patients. Similar results were obtained in
the addition of another NF-kB inhibitor, SN50 (Supplemen-
tary Fig. S2). It is interesting that PDTC failed to repair the
osteogenic capacity of SLE-BMMSCs stimulated with dexa-
methasone (Dex), GP, and AA (Supplementary Fig. S3).
These results suggest that an enhanced NF-kB activity by
high level of TNF suppressed the BMP/Smad, rather than
other osteogenesis-related pathways in SLE patients.
GC is used extensively for the treatment of SLE. In this
study, we cannot eliminate the effect of GC received by these
patients. It is reported that GC alters bone metabolism at the
cellular and molecular levels not only by increasing osteo-
clastic action [55] but also by inhibiting osteoblastic growth
and differentiation [56,57]. Dex suppressed the BMP-2 in-
duced Smad1/5/8 activation in mouse myoblastic C2C12
cells in vitro [58]. We show here in the Supplementary Data
that Dex, at the concentration of 0.1 and 1 mM, reduced the
phosphorylation of Smad1/5/8 induced by BMP-2, but it
had no any effect on the NF-kB activation (Supplementary
Fig. S4). Therefore, theoretically, the NF-kB inhibitory
FIG. 5. The circulating levels of BMP-2 in patients with
SLE. *P< 0.05 SLE (n = 16) versus normal controls (n = 15).
Nor, normal controls; SLE, systemic lupus erythematosus.
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treatment cannot restore the inactivation of pSmad1/5/8
induced by GC. From above, we indicate that in SLE pa-
tients, with the treatment of GC, the suppressed BMP sig-
naling pathway is at least partially attributed to the
activation of NF-kB.
The inhibitory mechanism of NF-kB to Smad1/5/8 is not
fully elucidated. Inconsistent with our results, Yamazaki
et al. did not observe an inhibitory effect of TNF activated
NF-kB on the phosphorylation of Smad1, Smad5, and Smad8
or on the nuclear translocation of the Smad1-Smad4 com-
plex. NF-kB inhibited Smad pathway by interfering with the
DNA binding of Smad proteins to its target gene in MC3T3-
E1 [33]. Although we could not explain this discrepancy, the
discrepancy might depend on the stage of the osteoblast
differentiation, the type of the cell, and the methods of the
experiments and needed further investigation.
In conclusion, we have demonstrated an activated NF-kB
activity and NF-kB inhibited BMP/Smad signaling pathways
in BMMSCs derived from SLE patients. The activated NF-kB
pathway inhibits BMP-2-induced osteogenic differentiation
through downregulating Smad signaling. Thus, our results
may suggest a new approach to increasing osteoblastic dif-
ferentiation for the treatment of OP in SLE patients.
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